



ASX RELEASE
17 April 2013

Share Purchase Plan Cleansing Notice

In accordance with ASIC Class Order 09/425 (**CO 09/425**), Novogen Ltd (**Novogen**) (**ASX: NRT**) gives notice that:

1. Novogen will make offers to issue ordinary shares under a Share Purchase Plan (**SPP**) without disclosure under Part 6D.2 of the Corporations Act 2011 (**Cth**) (**Act**);
2. this notice is given in accordance with CO 09/425 and in particular, paragraph 7(f)(ii) of CO 09/425 which requires that the Company give this notice to ASC within the 24 hour period before the SPP offer;
3. as at the date of this notice, Novogen has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to Novogen; and
 - (b) section 674 of the Act; and
4. as at the date of this notice, Novogen confirms that there is no information that is "excluded information" (as defined in subsections 708A(7) and 708A(8) of the Act) which is required to be disclosed by Novogen.

Yours faithfully

Graham Kelly
Executive Chairman

For further information contact:

Graham Kelly
Executive Chairman
Novogen Ltd
Telephone: 0459 200 095
Email: Graham.Kelly@novogen.com
Website: www.novogen.com

Further information on the SPP

Please contact our share registry if you require further information.

The share registry contact details are:

Computershare Investor Services Pty Limited
Level 4, 60 Carrington Street, Sydney NSW 2000
1300 855 080 (within Australia) or +61 3 9415 4000 (outside Australia)

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on super-benzopyran and 'stealth' drug technologies. The Company's inaugural drug candidate is CS-6.

About CS-6

CS-6 belongs to a new class of drug candidates known (structurally) as super-benzopyrans displaying potent anti-cancer activity and demonstrating increased bio-availability to cancer cells ('stealth' technology). CS-6 shows broad anti- proliferative and cytotoxic activity against human cancer cells, with particular activity against human glioblastoma cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.

More information: www.novogen.com

Safe harbour statement

Certain statements made in this document and material referred to in this document that use the words "estimate", "project", "intend", "expect", "believe" and similar expressions are intended to identify forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (U.S.). These forward looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements.

Investors should be aware that there are no assurances that results will not differ from those projected.